Key Stocks to Watch on April 8: Infosys, L&T, Asian Paints, BPCL, and More

The domestic stock market is expected to see a gap-up start to trading on Wednesday, April 8. The GIFT NIFTY futures suggest that the NIFTY50 index will open 650 points higher. Here is a list of stocks that may remain in focus today.

Aurobindo Pharma: Aurobindo Pharma announced on Tuesday that it has received final approval from the US Food & Drug Administration (USFDA) for its generic version of dapagliflozin tablets, used to control blood sugar levels in people with type 2 diabetes. The approval is for strengths of 5 mg and 10 mg, which are bioequivalent and therapeutically equivalent to AstraZeneca AB’s Farxiga tablets.

Lupin: The pharma major also received approval from the USFDA for its abbreviated new drug application for Dapagliflozin Tablets, 5 mg and 10 mg. These tablets are bioequivalent to Farxiga and are approved for the same indications as the reference drug.

Infosys: Infosys has entered into a strategic partnership with Harness, an AI software delivery platform company. This collaboration aims to drive improvements in productivity, software engineering, AI governance, and time-to-market at scale. Infosys Topaz Fabric, a multi-layer AI fabric, will be integrated with the Harness Software Delivery Platform to enhance enterprise capabilities.

LIC: Shares of Life Insurance Corporation of India (LIC) are expected to be in focus on April 8, as the company is slated to hold a board meeting on April 13 to consider and recommend a proposal for the issue of bonus shares.

Oil-sensitive stocks: Crude oil-sensitive sectors such as oil marketing companies (OMCs), paints, tyres, upstream companies, and aviation will be in focus on April 8. Crude oil prices in the global market dropped below the $95 per barrel level during the early market hours, which could impact these sectors.

Rate-sensitive stocks: Shares of auto, real estate, and financial sector companies will be closely watched as the Reserve Bank of India (RBI) is set to announce its monetary policy decision at 10 AM on April 8. Market participants will closely track the central bank’s stance on interest rates, liquidity measures, and inflation outlook, as any change could directly impact borrowing costs, demand outlook, and overall sentiment for these sectors.

Punjab National Bank (PNB): State-owned Punjab National Bank (PNB) has signed a Memorandum of Understanding (MoU) with Government e-Marketplace (GeM) to strengthen financial access for sellers. This partnership offers multiple benefits to sellers, including quick access to collateral-free short-term loans against GeM purchase orders, thereby improving liquidity and easing cash flow challenges, especially for MSMEs and small businesses.

L&T and KEC International: Shares of L&T and KEC International will be in focus as the Middle East is a key market, accounting for a significant portion of their order books. A ceasefire in the region would ease logistics issues, supply chain disruptions, and project delays, improving revenue visibility and project timelines.

Arvind SmartSpaces: Realty firm Arvind SmartSpaces Ltd has partnered with Sigma Oxford Realtors to develop a housing project in Mumbai with an expected revenue of ₹2,400 crore. The project, located in Goregaon (West), Mumbai, has a total saleable carpet area of 0.67 million sq ft. Arvind SmartSpaces has a presence in Gujarat, the Mumbai Metropolitan Region (MMR), and Pune, with a total real estate development area of 111.4 million square feet.

GAIL: GAIL (India) Ltd has signed a long-term charter agreement with Greece-based Alpha Gas for the liquefied natural gas (LNG) carrier Energy Fidelity. The vessel, with a capacity of 174,000 cubic metres, is equipped with advanced propulsion and fuel-efficiency technologies aimed at lowering emissions. GAIL will use the carrier to import LNG from countries like the US and Russia, supporting India’s long-term energy security.

Biocon: Biocon Ltd announced the commercial launch of biosimilars Bosaya and Aukelso in the US, indicated for different serious bone conditions. Both products, previously approved by the USFDA, are now available by prescription nationwide. Biocon CEO & MD Shreehas Tambe noted that the US introduction of Bosaya and Aukelso marks a strategic expansion of their biosimilars portfolio, providing high-quality, affordable treatment options for patients with serious bone conditions.